Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed/refractory acute myeloid leukemia

[1]  X. Thomas,et al.  Treatment of Elderly Patients With Acute Myeloid Leukemia , 2017, Current Treatment Options in Oncology.

[2]  Z. Singh,et al.  Minimally-Myelosuppressive Asparaginase-Containing Induction Regimen for Treatment of a Jehovah’s Witness with mutant IDH1/NPM1/NRAS Acute Myeloid Leukemia , 2016, Pharmaceuticals.

[3]  S. Demo,et al.  Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition. , 2015, Blood.

[4]  S. Isom,et al.  High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly. , 2015, Leukemia research.

[5]  S. Wander,et al.  Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia. , 2015, Seminars in hematology.

[6]  E. Estey,et al.  Current challenges in clinical development of "targeted therapies": the case of acute myeloid leukemia. , 2015, Blood.

[7]  M. Minden,et al.  Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations. , 2014, Experimental hematology.

[8]  E. Sausville,et al.  Asparaginase in the treatment of non-ALL hematologic malignancies , 2014, Cancer Chemotherapy and Pharmacology.

[9]  J. Tamburini,et al.  Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. , 2013, Blood.

[10]  A. Iafrate,et al.  Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. , 2012, Blood.

[11]  D. Steensma,et al.  Boulevard of broken dreams: drug approval for older adults with acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  W. Hiddemann,et al.  Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  V. Avramis.  Asparaginases: A Successful Class of Drugs Against Leukemias and Lymphomas , 2011, Journal of pediatric hematology/oncology.

[14]  J. Lee,et al.  Dose Escalation Methods in Phase I Cancer Clinical Trials , 2009, Journal of the National Cancer Institute.

[15]  David Steele,et al.  Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: A Children's Oncology Group study (CCG‐1941) , 2006, Pediatric blood & cancer.

[16]  P. Gaynon,et al.  Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961). , 2004, Anticancer research.

[17]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Dillman,et al.  Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia--a Cancer and Leukemia Group B Study. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.